loading...| Preferred Name |
Levalbuterol |
|
| Synonyms |
|
|
| Definitions |
A short-acting sympathomimetic beta-2 adrenergic receptor agonist with bronchodilator activity. Levalbuterol binds to beta-2 adrenergic receptors in bronchial smooth muscle and activates intracellular adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels lead to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation of bronchial smooth muscles. The increased cAMP concentrations also inhibit the release of inflammatory mediators, especially from mast cells. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C74196 |
|
| CAS_Registry |
34391-04-3 |
|
| CHEBI_ID |
CHEBI:8746 |
|
| Chemical_Formula |
C13H21NO3 |
|
| code |
C74196 |
|
| Contributing_Source |
FDA |
|
| definition |
A short-acting sympathomimetic beta-2 adrenergic receptor agonist with bronchodilator activity. Levalbuterol binds to beta-2 adrenergic receptors in bronchial smooth muscle and activates intracellular adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels lead to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation of bronchial smooth muscles. The increased cAMP concentrations also inhibit the release of inflammatory mediators, especially from mast cells. |
|
| FDA_UNII_Code |
EDN2NBH5SS |
|
| Has_Salt_Form |
http://purl.obolibrary.org/obo/NCIT_C83873 |
|
| in_subset | ||
| label |
Levalbuterol |
|
| Legacy Concept Name |
Levalbuterol |
|
| Preferred_Name |
Levalbuterol |
|
| prefixIRI |
NCIT:C74196 |
|
| prefLabel |
Levalbuterol |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0772501 |
|
| subClassOf |